Member Info for Alexios

Technical trade to high 20's

Perfect double bottom setup

10p Nominal

Fully funded till Jun2021

New respected NOMAD and Broker

https://twitter.com/Alexios1201/status/1350864786028957701?s=19

CLOSING MY SHORT FIRST THING IN THE MORNING AND SWITCHING TO LONGS TILL END OF MARCH
220-250p Target
+120% against the measly 10-15% profit shorting PFC is complete idiot trade.
All well priced in now...
Next week is going long and longer

This is not the real spread
You should know this by now being on lse for few years haha

This is the final bit

Snap back up next week

Buying well above 2p when FOMO kicks in

Buy low sell high

Perfect opportunity while under 1p

You will be jumping over yourselves when FOMO kicks in

Buy low sell high

Tr1 but not under 3% yet sadly

to 0.1p preferably lols

ETX tr1 under 3% next is my guess

bin told all gone now

Great

Thank you soupdragon

Will get noisy here soon

These reds are all buys bar few impatient clowns

Swing long

Was waiting for this funding since early autumn

While we wait for West Newton flowtest worth a look at #EOG
Stephen Williams on the board.
Europa oil and gas have 30% stake in Wressle.

https://www.europaoil.com/about.aspx

https://www.europaoil.com/operations.aspx

Oil producer in Middlands
Gas blocks owned in Ireland near largest Ireland gas producer
Oil Blocks in Morocco

Mcap under £6M

Expecting they will get noisy this year

Board reshuffled
The action will kick in here very soon

10Dec update

Cash position and loan facilities

At 30 November 2020 the Group held unaudited cash balances amounting to GBP3.8 million and, due to prudent cash management, its cash runway now extends into Q2 2021. The Group has received letters of intent from AOP Orphan International AG ("AOP"), a shareholder owning 10.7% of the Company's issued share capital, and Dr Christian Schweiger, a board member and holder of 3.5% of the Company's issued share capital, confirming that they are prepared to lend the Group up to EUR4.0 million and CHF1.0 million respectively in order to provide working capital for the Group. In total these amount to approximately GBP4.4 million which would extend the Group's cash runway until around the end of 2021

CASH RUNWAY UNTIL AROUND THE END OF 2021

Troll go and do one
Thanks

The drillbit should be at ~2500m into the belly of the mother nature today

£560k cash
£1.9M Freehold properties
£500k AIM Listing

£2.96M

Current Mcap ~£1M

Should be trading at min 1.6p
Current 0.65p https://t.co/x7FIWjp0rn

SPAC £900k Cash £900k Mcap

Special Purpose Acquisition Company

Shells are trading at multiples

PPG today hit over £4M Mcap, they have £200k cash Haha

http://www.globallegalchronicle.com/anemoi-international-ltds-main-market-ipo/

Anemoi International Ltd (AMOI) announced its Main Market IPO. AMOI is a special purpose acquisition company (SPAC) set up to explore the acquisition of a target company or business that may be undervalued or have unrealized growth potential and also meets AMOI’s broad investment criteria, including ownership of proprietary disruptive technology and/or assets that are strategically valuable.

Microneedles technology is similar to this one posted by vive earlier

https://www.researchgate.net/figure/Microneedle-patch-for-influenza-vaccination-A-The-microneedle-patch-contains-an-array_fig1_317979186

Emergex Vaccines Provides an Update on Agreement with Midatech Pharma
22nd November 2016/
Oxford, UK, 22 November 2016 – Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that it has paid an upfront technology access fee and option payment of £450,000 to Midatech Pharma (AIM: MTPH, NASDAQ: MTP), under the terms of the contract. This follows the licence granted to Emergex from Midatech Pharma, which was announced in January this year.

The exclusive licensing agreement covers the use of Midatech’s proprietary gold nanoparticle platform in the development of vaccines for influenza, meningitis, bacterial pneumonia, Ebola virus, Marburg virus and viruses within the Arbovirus class, such as Zika and Dengue. This is the first deployment of Midatech’s gold nanoparticles as a conventional vaccine for infectious diseases.

Under the agreement, the licence, together with the Service and Manufacturing Agreement for both the synthesis and development manufacturing of cGMP material for clinical trials, was novated from Emergex Vaccines Limited to a related entity, Emergex Vaccines Holding Limited (“Emergex”), a private UK biotechnology company focused on developing synthetic T-cell vaccines against new and emerging infectious diseases.

Midatech will continue to be entitled to receive certain milestone and royalty payments, as well as service fees, as part of the arrangement